S3 - ALS: Disease Mechanism and Therapeutics

Event Time: Sunday April 23, 2017 1:00 pm to 3:00 pm
Topic(s): Neuromuscular and Clinical Neurophysiology (EMG)
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:24 PM 003 Postnatal CRISPR-mediated genome editing prolongs survival in a mouse model of amyotrophic lateral sclerosis Zachary Kennedy
Disclosure:
Dr. Kennedy has nothing to disclose.

1:36 PM 004 Plasma Neurofilament Heavy Chain Levels correlate with disease severity and progression on multiple clinical outcomes in Amyotrophic Lateral Sclerosis (ALS) Steve Han, MD PhD
Disclosure:
Dr. Han has received personal compensation for activities with Biogen Idec as an employee. Dr. Han holds stock and/or stock options in Biogen Idec.

1:48 PM 005 Distinct patterns of disease progression in SOD1-associated familial ALS: A study of 25 mutations. Pooled analysis of two trials of pyrimethamine in familial ALS. Pantelis P. Pavlakis, MD
Disclosure:
Dr. Pavlakis has nothing to disclose.

2:00 PM 006 Immuno-modulation in Amyotrophic Lateral Sclerosis- A Phase II Study of Safety and Activity of Low Dose Interleukin-2 (IMODALS study) Gilbert Bensimon, MD
Disclosure:
Dr. Bensimon has nothing to disclose.

2:12 PM 007 The NEALS Randomized, Placebo Controlled Trial of Diaphragm Pacing in Patients with ALS Jonathan Katz, MD
Disclosure:
Dr. Katz has nothing to disclose.

2:24 PM 008 The polymorphisms of CX3CR1 gene influence ALS survival in an Italian population-based study Cristina Moglia
Disclosure:
Dr. Moglia has nothing to disclose.

Register Now

Related Courses